Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | DGKA | P23743 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | PAM | P19021 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11797960 | 0.92 | TSHR (0.50) | ALDH1A1DGKACES1CES2TSHR | |
| SCHEMBL11798021 | 0.92 | TSHR (0.50) | ALDH1A1DGKACES1CES2TSHR | |
| SCHEMBL11793562 | 0.92 | TSHR (0.50) | ALDH1A1DGKACES1CES2TSHR | |
| SCHEMBL11799548 | 0.92 | TSHR (0.50) | ALDH1A1DGKACES1CES2TSHR | |
| SCHEMBL11577758 | 0.92 | TSHR (0.50) | ALDH1A1DGKACES1CES2TSHR | |
| SCHEMBL6322226 | 0.88 | ALDH1A1 (0.46) | ALDH1A1TP53CES1CES2TSHR | |
| SCHEMBL11792756 | 0.84 | FAAH (0.51) | TP53DGKACES1LMNAMAPT | |
| SCHEMBL7684299 | 0.84 | FAAH (0.51) | TP53DGKACES1LMNAMAPT | |
| SCHEMBL7684306 | 0.84 | FAAH (0.51) | TP53DGKACES1LMNAMAPT | |
| SCHEMBL6313594 | 0.80 | DGKA (0.39) | ALDH1A1TP53DGKACES1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250946-A1 | Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides | PHARMASSET, INC. | 2005-11-10 | — | — | US | disclosed |
| US-6927291-B2 | Method for the synthesis of 2′,3′-dideoxy-2′,3′-didehydronucleosides | PHARMASSET, LTD. (US) | 2005-08-09 | — | — | US | disclosed |
| CN-1505635-A | Synthesis method of 2 ', 3' -dideoxy-2 ', 3' -didehydronucleoside | — | 2004-06-16 | — | — | CN | disclosed |
| EP-1363927-A2 | METHOD FOR THE SYNTHESIS OF 2',3'-DIDEOXY-2',3'-DIDEHYDRONUCLEOSIDES | Pharmasset Limited (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20020198224-A1 | Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides | GILEAD PHARMASSET LLC | 2002-12-26 | — | — | US | disclosed |
| WO-2002070533-A2 | METHOD FOR THE SYNTHESIS OF 2',3'-DIDEOXY-2',3'-DIDEHYDRONUCLEOSIDES | PHARMASSET LTD. (BB) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198224-A1 | Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides | DUT, DUS2, DERA | ALDH1A1 853/4885TP53 4163/4885DGKA 486/4885 |
| US-20050250946-A1 | Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides | DUT, DERA, DUS2 | ALDH1A1 837/4885TP53 4104/4885DGKA 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.